Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2010 - 2025)

Cumberland Pharmaceuticals (CPIX) has 16 years of Capital Expenditures data on file, last reported at -$1.0 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 100.04% year-over-year to -$1.0; the trailing twelve-month figure through Mar 2026 stood at $50273.0 (down 30.63% YoY), and the FY2025 full-year result was $97903.0, up 47.31% from the prior year.
• Capital Expenditures slipped to -$1.0 in Q4 2025, from $23788.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $137255.0 in Q2 2022 to a low of -$153528.0 in Q4 2022.
• A 5-year average of $32565.6 and a median of $26736.0 in 2022 frame the typical range for Capital Expenditures.
• Peak annual rise in Capital Expenditures reached 810.6% in 2022, while the deepest fall reached 1797.0% in 2022.
• Tracing CPIX's Capital Expenditures over 5 years: stood at $9047.0 in 2021, then plunged by 1797.0% to -$153528.0 in 2022, then surged by 131.7% to $48673.0 in 2023, then plunged by 95.31% to $2283.0 in 2024, then plunged by 100.04% to -$1.0 in 2025.
• Business Quant data shows CPIX's Capital Expenditures at -$1.0 in Q4 2025, $23788.0 in Q3 2025, and $26486.0 in Q2 2025.